Tech Companies Are Breeding Grounds for Some Big Data Life Science Company Executives
Summary
“We believe our technology will change the scale of what is possible in proteomics in an effort to enable significant advancements in drug development and help revolutionize the way biomedical research is conducted,” Patel said of his company earlier this year. Truveta’s platform harnesses data from millions of patients and care facilities to assist researchers in developing new therapeutics and treatment options. Another CEO highlighted by GeekWire is Daphne Koller of Insitro, a company that uses predictive models to accelerate target selection, design and develop effective therapeutics. On the company website, Koller explains that Inistro leverages the tools of biology to “generate high-quality, large data sets optimized for machine learning, allowing us to unleash the full potential of modern computational approaches.” Also, in 2020, Insitro raised $143 million in a Series B financing round. The fourth CEO highlighted by GeekWire is Naveen Jain, head of Viome Life Sciences, which earlier this year received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its proprietary mRNA analysis technology combined with its next-generation AI platform.